AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38640617
Drug: GATT-Patch
RxNorm normalized name: Gattex
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GATT-Patch
Trial: 38640748
Drug: PF-06939999 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06939999 0.5 mg q.d. to 6 mg b.i.d. (part 1 dose escalation)
Trial: 38640748
Drug: PF-06939999 6
RxNorm normalized name: FERMENT COMPLEX 6/PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06939999 6 mg q.d. (part 2 dose expansion)
Trial: 38640958
Drug: 3HP (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP (weekly isoniazid plus rifapentine for 3 months)
Trial: 38640958
Drug: 9H (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9H (daily isoniazid for 9 months)
Trial: 38641363
Drug: Stopping proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping proton pump inhibitors (PPIs) for 1 and 2 weeks
Trial: 38641363
Drug: Acidic bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic bile salt solutions (ABS) treatment in Barrett's cells
Trial: 38641363
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of BO spheroids after ABS treatment
Trial: 38641716
Drug: PROactive daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROactive daily diary
Trial: 38641768
Drug: L-PF-35 Dyspnea
RxNorm normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PF-35 Dyspnea domain score
Trial: 38641773
Drug: SCRT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCRT (25 Gy in five fractions over 1 week) plus chemotherapy (4 cycles of CAPOX or 6 cycles of mFOLFOX) and Cadonilimab
Trial: 38641773
Drug: SCRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCRT plus chemotherapy and Cadonilimab
Trial: 38641998
Drug: Sibeprenlimab (intravenous)
RxNorm normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibeprenlimab (intravenous)
Trial: 38642245
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (ET) as first-line treatment
Trial: 38642245
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (ET) as second-line treatment
Trial: 38642937
Drug: ivonescimab 20
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivonescimab 20 mg/kg every 2 weeks
Trial: 38643311
Drug: Capivasertib 400
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib 400 mg BID (4 days on/3 days off)
Trial: 38643311
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg (alone on day 1, and on days 8 and 12 with capivasertib)
Trial: 38643346
Drug: Ruxolitinib (RUX)
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (RUX) 15 mg twice daily and methylprednisolone (MP) 40 mg every other day
Trial: 38643346
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of Lenalidomide (LEN) 10 mg once daily on days 1-21 within a 28-day cycle to RUX and MP
Trial: 38643547
Drug: AZD1222 COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1222 COVID-19 vaccine (two doses)
Trial: 38643782
Drug: Optimised medical
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised medical treatment
Trial: 38644146
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg orally twice daily with ADT + docetaxel
Trial: 38644588
Drug: First-line infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First-line infliximab treatment
Trial: 38647654
Drug: AG-920 (Articaine)
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-920 (Articaine) ophthalmic solution
Trial: 38648264
Drug: Kaplan-Meier curve
RxNorm normalized name: Curae
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Kaplan-Meier curve for therapy escalation
Trial: 38648575
Drug: Liposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal irinotecan (70 mg/m2 IV)
Trial: 38648580
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment continued
Trial: 38648580
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment stopped
Trial: 38648814
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1 g over 10 min followed by 1 g over 8 h)
Trial: 38648814
Drug: Placebo (saline;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline; matched dosing regimen)
Trial: 38648863
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg linzagolix with add-back therapy (ABT)
Trial: 38648863
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg linzagolix alone
Trial: 38649069
Drug: Heparin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (10 IU/mL and higher)
Trial: 38649096
Drug: Dietary docosahexaenoic
RxNorm normalized name: docosahexaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary docosahexaenoic acid (DHA); specific dosage and duration not mentioned.
Trial: 38649279
Drug: Volume-derived positron-emission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-derived positron-emission tomography (PET) parameters assessed 6-8 weeks after the start of immune checkpoint inhibitors (ICPIs)
Trial: 38649522
Drug: Shorter ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Shorter ocrelizumab infusion (2-h)
Trial: 38649522
Drug: Conventional ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional ocrelizumab infusion (3.5-h)
Trial: 38649595
Drug: Rilematovir (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilematovir (low or high dose)
Trial: 38649826
Drug: Intermediate cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate cervical plexus block (IC) with 15 ml of bupivacaine 0.25% administered to each side
Trial: 38649826
Drug: Cervical erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical erector spinae block (ES) with 15 ml of bupivacaine 0.25% administered to each side at the C6 level
Trial: 38649937
Drug: ICG-guided targeted
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-guided targeted laser (IGTL) combined with intravitreal injections (IVI) of anti-VEGF
Trial: 38649937
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections (IVI) of anti-VEGF solely
Trial: 38650037
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus lenvatinib (tislelizumab 200 mg every three weeks plus lenvatinib 12 mg for bodyweight ≥ 60 kg or 8 mg for bodyweight < 60 kg once daily)
Trial: 38650039
Drug: Early progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early progressive resistance exercises (weekly supervised physiotherapy sessions and home exercises)
Trial: 38650055
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day edoxaban for 12 months
Trial: 38650055
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day edoxaban for 12 months
Trial: 38650075
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) treatment for 6 months postoperatively
Trial: 38650075
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no PEMF treatment)
Trial: 38650969
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers and Oxandrolone (BBOX)
Trial: 38651107
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT-A) injection, specifically abobotulinumtoxinA, median total dose 500 units, injected into biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%).
Trial: 38652564
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy initiation (ARTi)
Trial: 38652564
Drug: Acute antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute antiretroviral therapy initiation (ARTi)
Trial: 38652666
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for all patients
Trial: 38652691
Drug: Brief intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intervention including enhanced communication skills, goal setting, safer sex behaviors, drug refusal skills, and life satisfaction.
Trial: 38652978
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate variability biofeedback (HRV-BF) training sessions in addition to pharmacological standard therapy
Trial: 38652978
Drug: Standard therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapies for 10 weeks (Control group)
Trial: 38652999
Drug: Cenobamate 100
RxNorm normalized name: cenobamate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 100 mg/day
Trial: 38653508
Drug: Epirubicin (3.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (3.75, 7.5 or 15 mg/m2)
Trial: 38653618
Drug: Empagliflozin 25mg
RxNorm normalized name: EMPAGLIFLOZIN 25MG TAB
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 25mg once daily for three months
Trial: 38653618
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily for three months
Trial: 38653808
Drug: Acacia fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia fiber (AF) 10 g
Trial: 38653808
Drug: Probiotic Bifidobacterium
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Bifidobacterium Lactis (BLa80) 4 g
Trial: 38653903
Drug: iGlarLixi (Suliqua)
RxNorm normalized name: Ceratonia siliqua whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi (Suliqua) administered once daily
Trial: 38653979
Drug: rAAV2/8-hCYP4V2 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2/8-hCYP4V2 gene therapy (single unilateral subretinal injection of 7.5 × 10^11 vg)
Trial: 38653983
Drug: Umbilical cord-derived
RxNorm normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered at escalating doses of 0.5 × 10^6 cells/kg.
Trial: 38654329
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) provided by general practitioners or general practice staff after a 2-day PST course
Trial: 38654416
Drug: Highly effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly effective disease-modifying therapy
Trial: 38654416
Drug: Moderately effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately effective disease-modifying therapy
Trial: 38654416
Drug: Overall disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall disease-modifying therapy exposure
Trial: 38654422
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg once daily for 24 weeks
Trial: 38654422
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg once daily for 24 weeks
Trial: 38654422
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once daily for 24 weeks
Trial: 38654422
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg at 12 weeks
Trial: 38654422
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg at 12 weeks
Trial: 38655676
Drug: NTHi vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi vaccine antigens
Trial: 38655842
Drug: TAF/EVG inserts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF/EVG inserts (20 mg/16 mg) administered rectally
Trial: 38655990
Drug: Probiotic drink
RxNorm normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic drink containing Actiregularis strain (5×106 cfu/ml) added to maternal diet once daily for 15 days
Trial: 38655998
Drug: Rocuronium priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium priming (10% of the rocuronium dose administered 3 min before induction)
Trial: 38656229
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone antagonist degarelix
Trial: 38656355
Drug: Aronia melanocarpa
RxNorm normalized name: ARONIA MELANOCARPA FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia melanocarpa extract (AME) 180 mg anthocyanins/day
Trial: 38656557
Drug: Alpibectir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpibectir (0.5 to 40 mg) administered as single daily doses in fasted and fed conditions.
Trial: 38656557
Drug: Alpibectir (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpibectir (5 to 30 mg) administered once daily for 7 days in multiple ascending doses.
Trial: 38656557
Drug: Alpibectir under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpibectir under fed conditions (10 mg).
Trial: 38656557
Drug: Alpibectir (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpibectir (various doses) in multiple ascending doses.
Trial: 38656736
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894 (200 mg)
Trial: 38656736
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894 (50 mg and 100 mg)
Trial: 38657084
Drug: MVA-BN-Filo, Ad26.ZEBOV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart (n = 79)
Trial: 38657084
Drug: Ad26.ZEBOV, MVA-BN-Filo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart (n = 322)
Trial: 38657084
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine regimens (14-day and 28-day)
Trial: 38657201
Drug: Teclistamab (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab (1.5 mg/kg)
Trial: 38657730
Drug: Sublingual Buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Buprenorphine with taper
Trial: 38657730
Drug: Extended-release Buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release Buprenorphine with taper
Trial: 38657999
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) treatment with moisturising cream, performed at 630 nm two times per week in palmoplantar areas (4 J/cm²)
Trial: 38657999
Drug: Sham PBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham PBM treatment with moisturising cream
Trial: 38658012
Drug: Perioperative diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative diabetes treatment
Trial: 38658024
Drug: Pamiparib, Tislelizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib, Tislelizumab, Bevacizumab, and Nab-Paclitaxel (biomarker-driven combinatorial therapies)
Trial: 38658392
Drug: Novel PSMA-targeting
RxNorm normalized name: Gallium-68 PSMA
DrugBank: Gallium-68 PSMA (DB16303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel PSMA-targeting radionuclide therapy agents
Trial: 38658485
Drug: Anti-TNFα agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα agents
Trial: 38658485
Drug: Anti-TNFα agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα agents (top 40% effect score distribution)
Trial: 38658877
Drug: Psilocybin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (2 mg and 5 mg)
Trial: 38659046
Drug: LCAR-B38M CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCAR-B38M CAR T-cell therapy
Trial: 38659046
Drug: Subsequent therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapies after PD
Trial: 38659187
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) oxygenation at flow rates of 50-60 L/min
Trial: 38659334
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks
Trial: 38662320
Drug: Ganglionic local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion with a total volume of 2 ml injected into the parapharyngeal space and its 'medial compartment'.
Trial: 38662364
Drug: Postoperative pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative pelvic radiation using hypofractionated IMRT with 40 Gy in 16 fractions combined with concurrent chemotherapy
Trial: 38662372
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg IV, max 1000 mg)
Trial: 38662372
Drug: Modified higher-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified higher-dose regimen of abatacept
Trial: 38662779
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC) adherence measured over 95 days
Trial: 38662779
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC) adherence for hemorrhagic events
Trial: 38662779
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC) adherence for ischemic events
Trial: 38662979
Drug: Vidofludimus calcium
RxNorm normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidofludimus calcium 10 mg
Trial: 38662979
Drug: Any dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any dose of vidofludimus calcium
Trial: 38662991
Drug: ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibrutinib 560 mg and venetoclax 400 mg once daily
Trial: 38662991
Drug: Elective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective treatment interruption (ETI) for patients in MRD-negative CR
Trial: 38662991
Drug: Time-to-treatment failure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-to-treatment failure (TTF)
Trial: 38662991
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with venetoclax-ibrutinib
Trial: 38663539
Drug: Levonorgestrel 1.5
RxNorm normalized name: levonorgestrel 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 1.5 mg (LNG1X)
Trial: 38663539
Drug: Levonorgestrel 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 3.0 mg (LNG2X)
Trial: 38663539
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate 30 mg (UPA)
Trial: 38663582
Drug: Individualised, escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised, escalated fraction dose of radiotherapy (24 x 3.0-5.4 Gy) with either sequential or concurrent chemoradiotherapy, or radiotherapy only.